FDA to weigh easing limits on unproven peptides BPC 157: The peptide with big claims and scant evidence STAT FDA Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility Warning Letters MedShadow Foundation The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions August 11, 2025: The FDA voices concern about sites that supply compounding ingredients Partnership for Safe Medicines FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News